Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Filings indexed 374 across all filing types
Latest filing 2026-05-07 Quarterly Report
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Quarterly Report 2026
Quarterly Report
2026-05-07 English
Quarterly Report 2026
Quarterly Report
2026-05-07 English
Regulatory Filings 2026
Regulatory Filings
2026-05-06 English
NOTICE OF ANNUAL GENERAL MEETING IN IMMUNOVIA AB (PUBL)
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice and proxy solicitation sent to shareholders of Immunovia AB for its Annual General Meeting. It includes the meeting agenda, proposed resolutions, instructions for voting and proxies. This fits the definition of a “Proxy Solicitation & Information Statement” (PSI) rather than an actual AGM presentation or a simple regulatory announcement.
2026-04-13 English
KALLELSE TILL ÅRSSTÄMMA I IMMUNOVIA AB (PUBL)
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled “Kallelse till årsstämma” and contains the formal notice to convene the Annual General Meeting of Immunovia AB, including instructions for participation, proxy rules, the full meeting agenda and detailed proposals on items to be voted on. It is sent to shareholders to provide meeting information and solicit votes. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-13 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'BOKSLUTSKOMMUNIKÉ 2025' (Year-end Report 2025) and contains comprehensive financial statements, including income statements, balance sheets, and cash flow statements for the period October-December 2025 and the full year. It includes a CEO letter, management commentary on business performance, and key financial metrics. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q4 2025
2026-02-24 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.